Solasia Pharma K.K. officially announced that an organoarsenic drug “DARVIAS® Injection 135mg” has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma.
TOKYO--(BUSINESS WIRE)-- Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/
Contacts
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)
info@solasia.co.jp
Source: Solasia Pharma K.K.
View this news release online at:
http://www.businesswire.com/news/home/20220822005303/en
